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Abstract
The serine-protease hepsin is one of the most prominently overexpressed genes in human prostate carcinoma.
Forced expression of the enzyme in mice prostates is associated with matrix degradation, invasive growth, and
prostate cancer progression. Conversely, hepsin overexpression in metastatic prostate cancer cell lines was reported
to induce cell cycle arrest and reduction of invasive growth in vitro. We used a system for doxycycline (dox)-inducible
target gene expression in metastasis-derived PC3 cells to analyze the effects of hepsin in a quantitative manner. Loss
of viability and adhesion correlated with hepsin expression levels during anchorage-dependent but not anchorage-
independent growth. Full expression of hepsin led to cell death and detachment and was specifically associated with
reduced phosphorylation of AKT at Ser473, which was restored by growth on matrix derived from RWPE1 normal
prostatic epithelial cells. In the chorioallantoic membrane xenograft model, hepsin overexpression in PC3 cells re-
duced the viability of tumors but did not suppress invasive growth. The data presented here provide evidence that
elevated levels of hepsin interfere with cell adhesion and viability in the background of prostate cancer as well as
other tissue types, the details of which depend on the microenvironment provided. Our findings suggest that over-
expression of the enzyme in prostate carcinogenesis must be spatially and temporally restricted for the efficient
development of tumors and metastases.
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Introduction
Prostate cancer (PCa) is the most frequently diagnosed tumor entity
in men [1]. Despite considerable advances in the identification of
molecular changes [2,3], the interplay of altered genes and proteins
in the progression of prostate tumors is still poorly understood. Micro-
array expression profiling studies identified the hepsin (HPN ) gene
as one of the most prominently overexpressed genes in PCa (see
www.oncomine.org [4,5]). Hepsin belongs to the hepsin/TMPRSS/
enteropeptidase subfamily within the class of type II transmembrane
serine proteases [6]. The enzyme was found to cleave several biologic
substrates including blood coagulation factor VII [7], pro–hepatocyte
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growth factor [8], pro–urokinase-type plasminogen activator [9], epi-
dermal growth factor receptor [10], as well as the β3-subunit (LAMB3)
of laminin 332 (Ln-332) [11], an extracellular matrix (ECM) mole-
cule, which is part of the healthy prostate but frequently lost in PCa
[12]. Tissue-specific overexpression of hepsin in prostates of trans-
genic mice led to matrix destabilization and reduced levels of Ln-
332 [13]. In the LPB-tag mouse, a model for high-grade prostate
intraepithelial neoplasia (HG-PIN) due to expression of the SV40
large T antigen in the prostate epithelium, the same genetic modifica-
tion led to metastasized PCa. In an orthotopic mouse model, tumor
weight and prostate-specific antigen levels correlated with hepsin ex-
pression in the transplanted cells and were reduced after administration
of PEGylated Kunitz domain-1, a serine protease inhibitor with con-
siderable specificity for hepsin [14]. Thus, hepsin cleaves a variety of
tumor-relevant substrates, and its proteolytic activity is supposed to
play an important role during matrix remodeling in PCa.
Interestingly, hepsin overexpression is frequently lost in PCa me-
tastases [4]. Furthermore, forced expression of the gene in the PC3
PCa cell line, which is derived from a bone metastasis and displays
low endogeneous levels of hepsin, had been shown to evoke a G2 cell
cycle arrest, which was accompanied by reduced invasiveness in vitro
[15]. HPN overexpression was also found to confer growth suppres-
sive and proapoptotic effects in endometrial and ovarian cancer cell
lines [16,17]. However, others generated stable hepsin transfectants
in PC3- and LnCaP-PCa cell lines without observing any growth
suppressive effects [9,18], which challenged the findings cited. The
reasons for the contradictory results have not been resolved to date,
and functional studies on hepsin-associated signaling to resolve the
“hepsin paradox” [19] are lacking. Thus, the exact role of hepsin in
PCa, as well as its diagnostic and therapeutic value, remained unclear.
It has been suggested that the level of hepsin expression may in-
fluence cell viability, and the in vivo effects are mediated by specific
hepsin substrates present in the tumor stroma [14,19]. To test this
hypothesis, we used an isogenic cell line technology for inducible tar-
get gene overexpression to characterize the effects of HPN in both
PC3 metastatic PCa and in HEK293 nontumorigenic human em-
bryonic kidney cells. We found that hepsin overexpression led to
growth suppression in both cell lines. In PCa cells, hepsin-mediated
effects involve cell adhesion-associated signaling and can be modu-
lated by expression dosage as well as by the ECM provided.
Materials and Methods
Cell Culture and Transfections
Cells were cultivated using standard conditions (37°C, 5% CO2,
>95% humidity). For stable transfections, we used GeneJammer re-
agent (Stratagene, Waldbronn, Germany) following the manufac-
turer’s instructions.
RWPE1 cells (ATCC no. CRL-11609; LGC Standards, Wesley,
Germany) were cultivated in K-SFM-medium supplemented with
50 μg/ml bovine pituitary extract and 5 ng/ml epidermal growth fac-
tor. Genetically engineered derivatives of the PC3 PCa cell line
(ATCC no. CRL-1435) were cultivated in Dulbecco modified Eagle
medium containing high glucose, GlutaMAX (Invitrogen, Darmstadt,
Germany), 10% fetal calf serum (PAA, Pasching, Austria), and pen-
icillin (100 U/ml)/streptomycin (100 μg/ml) (PAA). The cells had
been genetically engineered as follows: A vector containing a Flp re-
combinase target (FRT) site was stably transfected into PC3 cells for
a subsequent site-specific integration of expression vectors, giving rise
to the PC3L1 clone. PC3L1 had been validated for single integration
of the FRT site and for inducible and homogeneous target gene over-
expression after integration of a fluorescent reporter. We generated the
PC3L1-HPNand -VC isogenic sublines by integration of expression con-
structs containing the tet repressor gene (tetR) as well as a tetracycline-
responsiveCMVpromoter controlling the hepsin gene (accession number
DQ892119) in case of PC3L1-HPN. Flp-in T-REx293 cells (Invitrogen)
were cultivated as recommended. We used pcDNA5-FRT-TO and a
hepsin-containing derivative for the generation of the vector control
(-VC) and hepsin (-HPN) transfectant, respectively.
Preparation of ECM
PC3L1-VC cells and RWPE1 cells were grown to confluence dur-
ing 6 days and subsequently removed from cell culture dishes by in-
cubation in 20 mM EDTA for 2 hours at 37°C. ECM-coated dishes
were washed twice with phosphate-buffered saline (PBS) and subse-
quently used for cell culture experiments. For Western blot analysis,
ECM was prepared using a solubilization buffer from the Cultured
Cells Acellularization Kit (Sigma, Schnelldorf, Germany) according
to the manufacturer’s instructions. The preparations were concen-
trated by acetone precipitation, and pellets were solubilized in an ad-
equate volume of buffer containing 20 mM HEPES, 150 mM NaCl,
5 mM EDTA, 10% glycerin, 1% Triton X-100, and 20 μl/ml Pro-
tease Inhibitor Cocktail (Sigma).
Quantitative Real-time Polymerase Chain Reaction
Cells were grown for 48 hours after induction and harvested. RNA
was prepared using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
and reverse-transcribed using the SuperScript III enzyme (Invitrogen)
and oligo-dT primer according to themanufacturer’s instructions.Quan-
titative polymerase chain reaction (PCR) of complementary DNA
was performed on the LightCycler 480 System (Roche, Mannheim,
Germany). ABsolute QPCR Mix (2×; Thermo Scientific, Epsom, UK)
and TaqMan Gene Expression Assays (Applied Biosystems, Weiterstadt,
Germany:HPN,Hs01056332_m1; β-actin [ACTB],Hs99999903_m1)
were used with the following cycling conditions: 95°C for 15 min-
utes, 45 cycles of 95°C for 10 seconds, and 60°C for 1 minute. The
expression level of ACTB was used for normalization, hepsin gene
expression was calculated with the 2−ΔΔCt method [20] and related
to the vehicle-treated PC3L1-VC sample.
Western Blot Analysis
Cells were grown until 48 to 96 hours after induction and harvested
using HEPES buffer described above, which was supplemented with
PhosStop phosphatase inhibitor (Roche) when appropriate. Cell lysates
and ECM preparations were quantified using BCA assay (Fisher Sci-
entific, Ulm, Germany) according to the manufacturer’s instructions,
subjected to SDS-PAGE, and transferred to nitrocellulose membranes
(GE Healthcare, Freiburg, Germany).
Proteins were specifically detected with ab43858 (hepsin; Abcam,
Cambridge, United Kingdom), sc-94 (ERK1/2; Santa Cruz), sc-
7383 (p-ERK; Santa Cruz, Heidelberg, Germany), 9272 (AKT; Cell
Signaling, Frankfurt, Germany), 4051 (pAKTSer473; Cell Signaling),
4056 (pAKTThr308; Cell Signaling), ab55415 (LAMB3; Abcam),
ab6276 (β-actin; Abcam), ab7291 (α-tubulin; Abcam), and secondary
antibodies goat-antirabbit IgG–horseradish peroxidase sc-2030 (Santa
Cruz), goat antimouse IgG–horseradish peroxidase sc-2031 (Santa
Cruz) using ECL Western blotting reagent (GE Healthcare).
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Viability Assay
Cells were assayed for viability using the Cell Titer Blue assay
(Promega, Mannheim, Germany) according to the manufacturer’s in-
structions. Briefly, 3000 to 5000 cells/well were seeded in adhesive or
antiadhesive (HydroCell) 96-well microplates (Nunc, Langenselbold,
Germany). Seventy-two hours after dox treatment, one-fifth volume
of Cell Titer Blue reagent was added and incubated for 3 hours at
37°C. Cells were analyzed for resorufin-mediated fluorescence (excita-
tion, 544 nm; detection, 590 nm) in a microplate reader (Fluostar
Omega; BMG Labtech, Offenburg, Germany). Cell survival was cal-
culated as percentage of the untreated control, respectively. At least
three independent experiments were performed in triplicate.
Adhesion Assay
Cells were seeded to 24-well plates (100/mm2), treated with dox
or vehicle, and incubated for 72 hours. The plates were then washed
three times with PBS without Ca2+/Mg2+. Adhesion was determined
by neutral red staining of residual cells as described previously [21]
because the commonly applied crystal violet staining protocol [22]
was found to interfere with ECM substrates deposited before analy-
sis [23]. Briefly, cell cultures were incubated in an aqueous solution
of neutral red (0.012%) for 2 to 3 hours and washed with isotonic
saline. Neutral red was extracted using a mixture of H2O, ethanol,
and acetic acid (1:1:0.02) during shaking at room temperature. Ab-
sorbance was determined at 570 nm using the Fluostar Omega mi-
croplate reader. Cell adhesion was calculated as percentage of the
untreated control, respectively. At least three independent experi-
ments were performed in quadruplicate.
Cell Cycle Analysis
Cells were seeded in six-well plates at a density of 100/mm2 (all
PC3L1-VC populations and PC3L1-HPN untreated) or 200/mm2
(PC3L1-HPN dox treated). Six hours after seeding, cells were treated
with different amounts of dox diluted in PBS or vehicle alone, re-
spectively. Ninety-six hours after induction, all cells were collected,
washed, and fixed using ice-cold methanol. After methanol removal,
DNA content was stained with 7-amino-actinomycin (Sigma; 20 μg/ml)
and analyzed via flow cytometry using a FACS Calibur (BD Biosci-
ences, Heidelberg, Germany) and WinMDI software (Version 2.9,
The Scripps Research Institute, http://facs.scripps.edu/software.html).
Chicken Chorioallantoic Membrane Assay
The chorioallantoic membrane (CAM) assay was performed as de-
scribed previously [24], with minor modifications. PC3L1-VC and
PC3L1-HPN cells were treated with dox (100 ng/ml) or vehicle (PBS)
96 hours before transplantation. At day 8 of breeding, 700,000 cells
per egg (five eggs per group) were seeded on the CAM in a total vol-
ume of 20 μl (10 μl of growth factor–reduced Matrigel [no. 356231;
BD Biosciences] and 10 μl of growth medium with vs without dox
[final concentration, 100 ng/ml]). Fresh medium was supplied every
24 hours until day 11. At day 12, tumors and surrounding CAM were
sampled and fixed in PBS-buffered 4% formaldehyde solution, paraf-
fin embedded, and cut into 5-μm sections. The sections were either
stained by hematoxylin-eosin or in immunohistochemistry using a
Ki67-specific antibody (Dako, Hamburg, Germany). Apoptosis was
assessed by terminal deoxynucleotidyltransferase-mediated dUTP
nick end labeling (TUNEL; Roche) according to the manufacturer’s
instructions. Negative controls were performed by omitting the pri-
mary antibody. Absolute numbers and percentages of (positive) cells
in 22 to 25 regions of interest (ROIs) per experimental group were
determined. Exemplary evaluation by a second examiner yielded sim-
ilar results.
Results
Establishment and Validation of Isogenic PC3 PCa
Transfectants for Quantitative Analyses of
Hepsin-Mediated Effects
A PC3-clone providing dox-inducible overexpression of hepsin
(PC3L1-HPN) and a corresponding isogenic vector control clone
(PC3L1-VC) were generated by site-specific integration of the re-
spective expression construct in PC3L1. PC3L1 is a genetically en-
gineered subclone of the PC3 cell line, which had been validated
for strong, homogeneous, and inducible expression of target genes
inserted into a single FRT site (not shown). In the absence of dox,
both clones revealed minimal hepsin expression (Figure 1) and sim-
ilar growth characteristics, as determined by neutral red assay (not
shown). A dose-dependent increase of hepsin mRNA (Figure 1A)
and protein (Figure 1B) was observed in PC3L1-HPN but not in
PC3L1-VC after dox application 48 hours after induction. Real-time
PCR revealed promoter leakiness leading to a certain degree of hepsin
mRNA expression in PC3L1-HPN in the uninduced state (not
shown), which, however, did not result in detectable expression of
hepsin protein. Full induction of hepsin protein expression was
achieved at 500 pg dox/ml growth medium (Figure 1B).
Figure 1. Hepsin expression in isogenic PC3 transfectants at the
mRNA (A) and protein level (B) 48 hours after supplementation of
growth medium with different amounts of dox. (A) An equivalent
of 10 ng of RNA was subjected to reverse transcription and sub-
sequently quantified in real-time PCR for HPN mRNA content
using ACTB as a reference gene. HPN mRNA was found to corre-
late with the concentration of dox in PC3L1-HPN. Data are mean ±
SD of three technical replicates. Calculation was performed using
the ΔΔCt method, with mean expression of PC3L1-VC (untreated)
as a calibrator. (B) Thirty micrograms of total cell lysates was anal-
yzed in Western blot analysis using α-tubulin as a loading control.
Full expression of hepsin protein was achieved at 500 pg/ml.
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Figure 2. Viability and adhesion of PC3L1-HPN correlate inversely with hepsin expression levels 72 hours after induction: dose depen-
dence of cellular effects. (A) Whereas viability of PC3L1-VC was unaffected by dox, viability of PC3L1-HPN was gradually suppressed
with increasing concentrations of the inducer, becoming significant at 50 pg/ml (mean ± SD of four experiments performed in triplicate,
two-tailed t test). (B) Cell cycle analysis revealed a dose-dependent increase of cell death in PC3L1-HPN 96 hours after hepsin induction,
as indicated by elevated numbers of cells in sub-G1. (C) Phase-contrast microscopy revealed a dose-dependent loss of adhesion in
PC3L1-HPN but not in PC3L1-VC. Scale bar, 50 μm. (D) The number of adherent cells was significantly reduced in a dose-dependent
manner in PC3L1-HPN but not in PC3L1-VC cells (72 hours after hepsin induction, median ± MAD of three experiments performed in
quadruplicate, two-tailed t test).
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Graded Overexpression of Hepsin Leads to Dose-Dependent
Suppression of Viability, Loss of Adhesion, and Death of
PC3 Cells
To quantitatively characterize effects of hepsin on PC3 cells, we
compared PC3L1-HPN and PC3L1-VC 72 hours after treatment
with different doses of dox. Whereas viability of PC3L1-VC cells
was not affected by dox, we observed a dose-dependent loss of viability
in PC3L1-HPN cells, which was significant at 50 pg/ml and above
(Figure 2A). Cell cycle analysis revealed a dose-dependent increase
of PC3L1-HPN cells in the sub-G1 fraction, which is indicative for
cell death in the presence of hepsin (Figure 2B). Loss of viability
and cell death were associated with a markedly reduced adhesion of
PC3L1-HPN cells after hepsin induction (as detected by phase-
contrast microscopy; Figure 2C ), which was quantified in adhesion
assays using neutral red staining of cells remaining attached after rigor-
ous washing (Figure 2D). A comparison of viability and adhesion data
suggests that, at higher induction levels of hepsin, a percentage of non-
adherent cells contributed to overall viability (Figure 2, A and D).
Anchorage-Independent Growth Is Not Affected by
Overexpression of Hepsin in PC3 Cells
Under nonadhesive conditions, PC3 cells were previously reported
to escape detachment-induced apoptosis (anoikis), displaying a rate of
apoptotic cells in suspension culture of around 10% [25]. Srikantan
et al. [15] found a reduction in anchorage-independent growth of
PC3-hepsin transfectants in soft agar, when compared with vector
control cells. To investigate whether cell adhesion is a prerequisite
for the reduction of viability after hepsin expression, we performed
assays in antiadhesive tissue culture plates. In contrast to the loss of
viability in adhesive tissue culture plates, graded overexpression of
hepsin did not affect viability during anchorage-independent growth
(Figure 3).
Hepsin-Mediated Loss of Adhesion and Viability Correlates
with Reduced Phosphorylation of AKT at Ser473
PC3 cell growth and viability had been reported to critically depend
on phosphatidylinositol-3-kinase (PI3K) signaling [26–28]. AKT, an
effector of PI3K signaling, is phosphorylated at Thr308 by PDK1 in
the presence of phosphatidylinositol (3,4,5)-trisphosphate, the genera-
tion of which is catalyzed by PI3K and antagonized by PTEN activity,
respectively [29]. For full activation, AKT requires a second phosphoryla-
tion at Ser473, which could be mediated by the mTORC2 complex [30]
or, for example, by a mammalian target of rapamycin–independent pro-
tein complex containing rictor and integrin-linked kinase (ILK) [31].
We were interested in the phosphorylation state of AKT at Thr308
and Ser473, and in the phosphorylation state of the extracellular signal–
related kinases (ERK1/2), other important mediators of tumor cell vi-
ability, in response to hepsin expression in PC3 cells. Ninety-six hours
after induction, cells were subjected to preparation of phosphoprotein
and Western blot analysis. We found no alterations in the phosphor-
ylation states of ERK1/2 and AKT at Thr308, whereas AKT was al-
most completely dephosphorylated at Ser473 (Figure 4).
Figure 3. Hepsin expression levels do not affect anchorage-independent growth. (A) Seventy-two hours after treatment with different
amounts of dox, viability was altered neither in PC3L1-HPN nor in PC3L1-VC (mean ± SD of three experiments performed in triplicate).
(B) Phase-contrast microscopy revealed similar growth appearance in both cell lines, which was not affected by dox. Scale bar, 100 μm.
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ECM of Prostate Cells, but Not of PCa Cells, Restores AKT
Phosphorylation at Ser473 and Adhesion of Fully Induced
PC3L1-HPN Cells
Hepsin revealed particularly strong expression in HG-PIN, which is
suggested to be the precursor lesion of PCa [4]. In a mouse model,
hepsin overexpression in the prostate correlated with loss of Ln-332
[13]. LAMB3, a subunit of Ln-332, was afterward identified as a hepsin
substrate [11]. We therefore asked whether the ECM composition,
particularly the presence of Ln-332, could affect viability and adhesion
of hepsin-overexpressing PC3 cells.
We initially analyzed ECM deposited by nontumorigenic RWPE1
cells and PC3L1-VC cells for the presence of Ln-332. As expected,
we found a strong signal at ∼140 kDa representing LAMB3 in ECM
of RWPE1- but not of PC3L1-VC cells (Figure W1). We used ECM
of both cell lines deposited during 6 days of culture for comparative
analyses of cell viability, adhesion, and AKT phosphorylation during
forced expression of hepsin in PC3 cells. Seventy-two hours after
induction of hepsin, we found elevated viability of cells grown on
RWPE1-derived ECM, which was significant at dox concentrations
of 60 pg/ml and above (Figure 5A). Microscopic examination and
quantitative analysis revealed that adhesion of hepsin-overexpressing
cells could be predominantly restored on RWPE1- but not by PC3L1-
VC–derived ECM (Figure 5, B and C ). AKT phosphorylation at
Ser473 was largely maintained 48 hours after full induction of hepsin
on RWPE1- but not on PC3L1-VC–derived ECM. Interestingly,
Ser473 phosphorylation slightly decreased during elevated growth pe-
riods (72 and 96 hours) on RWPE1-derived ECM in the presence
of hepsin, suggesting that the ECM-mediated sustainability is tempo-
rarily limited (Figure 5D and Figure W2).
Cleavage of LAMB3 during Growth of PC3 Cells on
RWPE1-Derived Matrix
Using purified recombinant proteins, hepsin-mediated cleavage of
Ln-332 had been demonstrated by Tripathi et al. [11]. To test whether
the LAMB3 subunit of ECM-associated Ln-332 is specifically de-
graded in a dose-dependent manner by hepsin in our cell model, we
compared RWPE1-deposited ECM after a 96-hour growth period
of fully induced versus uninduced PC3L1-HPN and PC3L1-VC cells
by Western blot analysis. Besides the full-length LAMB3 protein, we
found cleavage fragments of LAMB3 in all ECM preparations (Fig-
ure 6). Thus, LAMB3 cleavage efficiency correlated neither with hepsin
expression levels nor with the presence of dox in our model.
Hepsin Overexpression Reduces the Viability of Tumors but
Does Not Prevent Invasive Growth of PC3 Cells in the CAM
Xenograft Model
Srikantan et al. [15] used a Boyden Chamber assay to demonstrate
that PC3 cells loose their invasive potential on forced expression of
hepsin. Our previous results support the hypothesis that hepsin-
mediated effects in PC3 cells are significantly influenced by the mi-
croenvironment. To test whether this holds true for invasive growth,
we used the CAM in vivo xenograft model for invasion and angio-
genesis [24] to compare untreated versus dox-treated PC3L1-HPN
and PC3L1-VC cells. Tumors (n = 5 for each cell line) were well
accepted and supported by the CAM, which is indicative for invasive
growth and blood supply by the host tissue. Hepsin-overexpressing
tumors revealed an altered appearance, which was characterized by a
more nodular growth and extended areas of connective tissue when
compared with more superficially growing tumors with high cell den-
sity from untreated PC3L1-HPN and PC3L1-VC (Figure 7A). Im-
munohistochemical analysis revealed a significantly reduced mitotic
index (as determined by Ki67 staining, P = 1.1e − 04) and cell den-
sity (P = 4.7e − 07), as well as a slightly higher density of apoptotic
cells (as determined by TUNEL staining, P = .0057) in dox-treated
versus untreated PC3L1-HPN–derived tumors (Figure 7B). Surpris-
ingly, we also detected a significantly reduced rate of apoptotic cells
in PC3L1-VC–induced versus uninduced tumors (P = .0019), which
demonstrates that daily administration of dox alone does not favor
apoptosis in our model system. In summary, the CAM assay reflected
cellular characteristics observed after hepsin overexpression in vitro
but did not support the hypothesis that overexpression of hepsin
suppresses invasive growth of PC3 cells.
Hepsin Suppresses Viability and Adhesion in Human
Embryonic Kidney HEK293 Cells
To assess whether the phenotype of hepsin-overexpressing PC3 cells is
prostate- (cancer-) specific or rather represents a tissue-independent gen-
eral response, we constructed inducible hepsin transfectants (-HPN)
and an isogenic vector control (-VC) in the Flp-In T-Rex 293 cell line,
a commercially available HEK293 derivative allowing dox-inducible ex-
pression of a target gene. At 48 hours after dox administration, Flp-in
T-Rex 293-HPN cells expressed hepsin, as determined by Western
blot analysis (Figure 8A). Cell viability of Flp-In T-Rex 293-HPN
was considerably lower than viability of Flp-In T-Rex 293-VC in the
absence of dox (not shown). It was further reduced significantly dur-
ing graded induction of hepsin, whereas we found no suppression
of viability in the empty vector control cell line (Figure 8B). Similar
to PC3L1-HPN, Flp-In T-Rex 293-HPN cells lost adhesion after
Figure 4. Overexpression of hepsin exclusively reduces phosphory-
lation of AKT at Ser473, whereas phosphorylation of AKT at Thr308, as
well as phosphorylation of ERK, remained constant. Ninety-six hours
after treatment with dox (100 ng/ml) or vehicle alone, PC3L1-HPN
and PC3L1-VC cells were harvested and lysed. Fifty micrograms of
phosphoprotein preparationswas subjected toWestern blot analysis
for the investigation of phosphorylation states of ERK, pAKTThr308,
pAKTSer473, aswell as total expression of ERK and AKT. Loading con-
trols were α-tubulin (for ERK) and β-actin (for AKT), respectively.
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induction of hepsin (Figure 8C). Full expression of hepsin led to reduced
AKT phosphorylation at Ser473 (Figure 8D). In summary, the effects ob-
served during hepsin overexpression in HEK293 cells closely resembled
those observed in PC3 cells, which suggests a rather general, cell-type–
independent response.
Discussion
Several groups established recombinant cancer cell lines overexpress-
ing hepsin, which were generated in a conventional manner by ran-
domized insertion of one or several copies of the gene into the cell
line’s genome, followed by antibiotic selection and proof of hepsin
Figure 5. The ECM composition regulates viability, adhesion, and AKT phosphorylation of hepsin-overexpressing PC3 cells. (A) For
PC3L1-HPN, growth on RWPE1-derived ECM confers significantly enhanced viability when compared with PC3-derived ECM at dox
concentrations of 60 pg/ml and above (72 hours after hepsin induction, mean ± SD of three experiments performed in triplicate,
two-tailed t test). (B) Phase-contrast microscopy revealed a dose-dependent loss of adhesion of PC3L1-HPN on PC3-derived matrix
but not on RWPE1-derived matrix (72 hours after hepsin induction) Scale bar, 50 μm. (C) PC3L1-HPN adhered significantly stronger
on RWPE1-derived matrix compared with PC3-derived matrix for all dox concentrations tested (72 hours after hepsin induction, median ±
MADof three experiments performed in quadruplicate, two-tailed t test). (D) RWPE1-derivedmatrix restored AKT-phosphorylation at Ser473 in
hepsin-overexpressing PC3L1 cells. At 48, 72, and 96 hours after treatment with dox or vehicle alone, cells were harvested and lysed. Fifty
micrograms of phosphoprotein preparations was subjected to Western Blot analysis for the investigation of AKT-phosphorylation at Ser473,
as well as total AKT protein. β-Actin was used as a loading control.
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expression [9,15–18]. Some groups reported a suppression of via-
bility and other tumor-relevant functions during growth in vitro
[15–17], whereas others found no hepsin-associated adverse effects.
The inconsistency of these data suggested a dosage-dependent ef-
fect because the expression levels in the recombinant cell lines were
not comparable and potential viability-suppressing effects of hepsin
counteracted the generation of strongly expressing recombinant
clones. To circumvent this drawback, we constructed cell lines with
strong, homogeneous, and inducible expression of hepsin, as well as
isogenic vector controls, for a thorough analysis of quantitative effects
of hepsin overexpression in PC3 metastatic PCa as well as HEK293
nontumorigenic human embryonic kidney cells. We found that hepsin
overexpression caused a dose-dependent loss of adhesion and viability
in both cell types during growth in conventional tissue culture plates,
which most probably interfered with the selection of strongly express-
ing recombinant clones in previous approaches. Loss of adhesion and
Figure 6. Analysis of LAMB3-cleavage inECMpreparations. RWPE1-
derived ECM was deposited during 6 days of growth to confluence
and subsequently used as a substrate for 96 hours of growth of
PC3L1-HPN and PC3L1-VC cells (with 100 ng/ml vs without dox) to
assess the impact of hepsin expression levels on LAMB3 cleavage.
After the incubation period, matrix was prepared, and 5 μg of each
preparation was subjected to Western blot analysis, together with
100 ng of rat Ln-332 serving as a positive control (ctrl). The presence
of the∼140-kDa band (corresponding to uncleaved LAMB3) as well
as additional smaller bands suggested a partial cleavage of LAMB3
during growth of all PC3 cell populations on RWPE1-derived ECM,
irrespective of hepsin expression levels or the presence of dox.
Figure 7. Full induction of hepsin expression reduces the mitotic index and elevates the density of apoptotic cells in tumors but does not
prevent invasive growth of PC3L1-HPN on the CAM. PC3L1-HPN and PC3L1-VC cells were grown for 96 hours in conventional cell
culture dishes with versus without dox (100 ng/ml) to ascertain full expression of hepsin before transplantation. At day 8 of breeding,
cells were seeded on the CAM (700,000 cells/egg) and further treated daily with dox or vehicle. At day 12 of breeding, transplants were
fixated and subjected to histologic examination. (A) Representative microscopic images of tumors derived from PC3L1-HPN treated with
vehicle alone (upper panel) or dox (lower panel). Hepsin-overexpressing tumors (lower panel) revealed extensive penetration of the CAM,
along with a high content of connective tissue and low cell density within tumor nodules. Ki67-positive nuclei are marked by arrow-
heads; TdT-positive nuclei are marked by arrows. (B) ROI analyses of tumors (n = 22-25 per experimental group) revealed a significant
reduction in Ki67-based mitotic index and total number of cells, as well as a significantly higher absolute number of TdT-positive cells/
ROI in hepsin-overexpressing tumors.
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viability were associated with a loss of AKT phosphorylation at Ser473,
which may at least explain the phenotype observed in PC3 PCa cells,
as these cells critically depend on PI3K signaling [26–28]. In PC3
cells, AKT phosphorylation and cell adhesion could be specifically re-
stored by growth on ECM deposited by nontumorigenic RWPE1
prostate epithelial cells.
The hepsin paradox as introduced by Valery Vasioukhin [19] de-
scribes the discrepancy between elevated levels of hepsin expression
in PCa on the one hand, and the growth suppressive effects of hepsin
overexpression in metastatic cancer cell lines on the other. Klezovitch
et al. [13] established transgenic mice, which revealed constitutive
prostate-specific overexpression of hepsin and demonstrated a marked
disorganization of the prostate ECM. The latter was characterized by
loss of Ln-332, diffuse organization of hemidesmosomes, and a per-
turbed structure of the borderline separating the stromal and epithelial
compartment of the organ. Furthermore, when crossed with the LPB-
tag mouse, a model for HG-PIN, double-transgenic mice developed
disruption of the epithelial structure in the prostate, adenocarcinoma,
and metastatic cancer. However, compared with LBP-tag mice, the
double-transgenic animals revealed no differences with regard to
Ki67-based mitotic index in the prostate. TUNEL staining revealed
a fourfold increase in apoptosis in double-transgenic animals. The
authors suggested that timing, microenvironment, and the level of
hepsin expression may be critical for the correct course of proteolytic
events during PC progression.
Basically, our data support the suggestions of Klezovitch et al. In
contrast to results of Srikantan et al. [15], who described a loss of
invasive growth of hepsin-overexpressing PC3 metastatic PCa cells
in vitro, we detected invasive growth of hepsin-overexpressing PC3
cells when transplanted on the CAM, although this was accompanied
Figure 8. Hepsin overexpression suppresses viability, adhesion, and phosphorylation of AKT at Ser473 in human embryonic kidney 293
cells. (A) Flp-in T-Rex 293-HPN and -VC cells were grown in the presence of the indicated amounts of dox for 96 hours. Thirty micro-
grams of total cell lysates was analyzed in Western blot analysis using β-actin as a loading control. Flp-in T-Rex 293-HPN revealed in-
ducible overexpression of hepsin, which was saturated at 100 ng/ml of dox. (B) Whereas viability of Flp-in T-Rex 293-VC was unaffected
by dox, viability of Flp-in T-Rex 293-HPN was gradually suppressed with increasing concentrations of the inducer, becoming significant
at 1 ng/ml (mean ± SD of three experiments performed in triplicate, two-tailed t test). (C) On dox induction, phase-contrast microscopy
revealed a loss of adhesion in Flp-in T-Rex 293-HPN but not in Flp-in T-Rex 293-VC (96 hours after treatment). Scale bar, 50 μm. (D)
Ninety-six hours after treatment with dox or vehicle alone, Flp-In T-Rex 293-HPN and Flp-In T-Rex 293-VC cells were harvested and lysed.
Fifty micrograms of phosphoprotein preparations was subjected to Western blot analysis for the investigation of AKT phosphorylation at
Ser473 as well as total AKT protein. β-Actin was used as a loading control.
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by reduced cell growth and density, as well as elevated apoptosis in
the xenografts. The conflicting data could originate from the differ-
ent microenvironments provided in the respective model systems.
Most available data, including our own, indicate that irrespective of
the cellular background, excessive overexpression of hepsin seems in-
compatible with adherent cell growth, unless cells receive a specific (ex-
tracellular) signal for adhesion and survival. We suggest that this signal
is provided by noncancerous ECM, for example, from prostate epithe-
lial cells. ECM remodeling during prostate carcinogenesis could then
execute a selective pressure on hepsin-overexpressing cells through loss
of this specific survival signal, resulting in reduced activity of AKT.
Our hypothesis explains the protein expression patterns observed by
Dhanasekaran et al. [4] in immunohistochemistry, who found that a
strong overexpression of hepsin is mainly restricted to HG-PIN lesions
(i.e., in the presence of “normal” prostate matrix), whereas advanced
stages of PCa revealed predominantly weak or moderate staining inten-
sities. Also, it implies that a thorough functional characterization of the
role of hepsin in the different stages of PCa requires both an authentic
genetic/posttranslational regulation and microenvironment.
The data presented here suggest that elevated levels of hepsin inter-
fere with a pathway, which regulates adhesion and results in AKT phos-
phorylation. Persad et al. [32] demonstrated a dependence of AKT
phosphorylation at Ser473 on the activity of ILK in PTEN-deficient
PCa cells, including PC3. This mechanism was further specified by
the identification of a molecular cooperation between ILK and rictor,
which was required for both regulation of AKT phosphorylation and
cancer cell survival [31]. A major function of ILK is the transmission
of extracellular signals through focal adhesion complexes [33]. It is
thus conceivable that the presence and/or the proteolytic activity of
hepsin directly affect this pathway through an interaction with integ-
rins or ECM ligands on the cell surface. Interestingly, interrogation of
expression data revealed a mutually exclusive pattern of HPN and ILK
expression in PCa, which is indicative for a functional role of ILK in
hepsin-mediated cellular effects [3].
Ln-332 represents a candidate ECM substrate for hepsin-mediated
proteolysis [11], which is downregulated in advanced prostate carci-
noma [12] and was found in RWPE1- but not in PC3-derived ma-
trix. Ln-332 provides adhesion and survival signals via focal adhesion
complexes and AKT signaling [34] and is an integral component of
adhesion contacts in epithelial cells [35]. Ln-332 as well as several
of its cleavage products was found to modulate relevant properties
of cancer cells [36,37]. Therefore, we speculated that the LAMB3
subunit could be a specific substrate of hepsin in our model system,
the cleavage of which could be required for the ECM-associated cel-
lular effects observed. Whereas we demonstrated a partial LAMB3
cleavage during growth of PC3 cells on RWPE1-deposited ECM,
we found neither a specificity for hepsin-overexpressing cells nor a
correlation with hepsin expression levels for this reaction. Instead,
LAMB3 was also cleaved efficiently by uninduced PC3L1-HPN and
PC3L1-VC, probably by matriptase, which was reported to be ex-
pressed in PC3 [38] and recently found to cleave LAMB3 in vitro
[39]. Thus, although Ln-332 presence and/or LAMB3 cleavage may
be critical for AKT phosphorylation at Ser473, adhesion, and viability
of hepsin-overexpressing PC3 cells on RWPE1-ECM, we could not
provide evidence for any relationship between LAMB3 cleavage and
the effects observed during hepsin overexpression in our model system.
While we established a relation between hepsin levels and adhesion-
dependent growth of PCa cells, detailed mechanisms for the effects
observed remain elusive. Surprisingly, application of the broad spec-
trum serine protease inhibitor 4-(2-aminoethyl)-benzensulfonylfluoride
(AEBSF) did not restore viability and adhesion of PC3L1-HPN after
hepsin induction but instead caused a significant loss of viability even
in PC3L1-VC (Figure W3), which suggests protease-independent
growth- and adhesion-suppressive effects in the presence of hepsin.
However, we were not able to determine the degree of hepsin inhibi-
tion in our experiment, which was a function of (i) hepsin expression
dynamics during induction, (ii) expression levels and dissociation con-
stants of other serine proteases affected by AEBSF, and (iii) stability
of AEBSF under cell culture conditions. Future studies using a more
specific, stable, and nontoxic hepsin inhibitor and/or functional anal-
ysis of a protease-dead mutant in the (isogenic) PC3L1 background
will help to determine whether the observed effects depend on the
proteolytic activity of the enzyme.
Understanding the exact mechanism of hepsin-mediated growth
suppression and cell death may reveal new therapeutic approaches
for PCa, as the presence and/or activity of the enzyme suppresses
PI3K/AKT signaling when placed in an adequate microenvironment.
A comprehensive knowledge of hepsin interactors or substrates at the
cell surface, as well as a delineation of the ubiquitous signaling axis,
which is affected by hepsin may offer the opportunity for a synthetic
lethal therapeutic intervention basing on the modulation of survival
signaling in hepsin-overexpressing tumors.
Acknowledgments
The authors thank Felicitas Genze and Andrea Schäfer for expert
technical assistance, Jan Mollenhauer for assignment of cells and vec-
tors, and Rainer Küfer for expert advice in the initialization phase of
the project.
References
[1] Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, and Boyle P (2007).
Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol
18, 581–592.
[2] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW,
Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of
TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310,
644–648.
[3] Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK,
Kaushik P, Cerami E, Reva B, et al. (2010). Integrative genomic profiling of hu-
man prostate cancer. Cancer Cell 18, 11–22.
[4] Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K,
Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic
biomarkers in prostate cancer. Nature 412, 822–826.
[5] Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, and Kristiansen G (2004).
Hepsin is highly over expressed in and a new candidate for a prognostic indica-
tor in prostate cancer. J Urol 171, 187–191.
[6] Bugge TH, Antalis TM, and Wu Q (2009). Type II transmembrane serine pro-
teases. J Biol Chem 284, 23177–23181.
[7] Kazama Y, Hamamoto T, Foster DC, and Kisiel W (1995). Hepsin, a putative
membrane-associated serine protease, activates human factor VII and initiates a
pathway of blood coagulation on the cell surface leading to thrombin formation.
J Biol Chem 270, 66–72.
[8] Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, and Moran P (2005).
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte
growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 579,
1945–1950.
[9] Moran P, Li W, Fan B, Vij R, Eigenbrot C, and Kirchhofer D (2006). Pro–
urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 281,
30439–30446.
[10] Chen M, Chen LM, Lin CY, and Chai KX (2010). Hepsin activates prostasin
and cleaves the extracellular domain of the epidermal growth factor receptor.
Mol Cell Biochem 337, 259–266.
588 Hepsin Modulates Adhesion and AKT Signaling Wittig-Blaich et al. Neoplasia Vol. 13, No. 7, 2011
[11] Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, and Quaranta
V (2008). Laminin-332 is a substrate for hepsin, a protease associated with pros-
tate cancer progression. J Biol Chem 283, 30576–30584.
[12] Hao J, Yang Y, McDaniel KM, Dalkin BL, Cress AE, and Nagle RB (1996).
Differential expression of laminin 5 (α3β3γ2) by human malignant and normal
prostate. Am J Pathol 149, 1341–1349.
[13] Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, and Vasioukhin
V (2004). Hepsin promotes prostate cancer progression and metastasis. Cancer
Cell 6, 185–195.
[14] Li W, Wang BE, Moran P, Lipari T, Ganesan R, Corpuz R, Ludlam MJ,
Gogineni A, Koeppen H, Bunting S, et al. (2009). Pegylated kunitz domain
inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Cancer Res 69, 8395–8402.
[15] Srikantan V, Valladares M, Rhim JS, Moul JW, and Srivastava S (2002). HEPSIN
inhibits cell growth/invasion in prostate cancer cells. Cancer Res 62, 6812–6816.
[16] Nakamura K, Nasu Y, Hongo A, Matsuo T, Kodama J, Ebara S, Nagai A, Abrzua
F, Kumon H, and Hiramatsu Y (2006). Hepsin shows inhibitory effects through
apoptotic pathway on ovarian cancer cell lines. Int J Oncol 28, 393–398.
[17] Nakamura K, Takamoto N, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H,
and Hiramatsu Y (2008). Hepsin inhibits the cell growth of endometrial cancer.
Int J Mol Med 22, 389–397.
[18] Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, and
Weissleder R (2008). Detection of early prostate cancer using a hepsin-targeted
imaging agent. Cancer Res 68, 2286–2291.
[19] Vasioukhin V (2004). Hepsin paradox reveals unexpected complexity of meta-
static process. Cell Cycle 3, 1394–1397.
[20] Livak KJ and SchmittgenTD (2001). Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−ΔΔC (T)) method. Methods 25, 402–408.
[21] Sailer R, Strauss WS, WagnerM, Emmert H, and Schneckenburger H (2007). Re-
lation between intracellular location and photodynamic efficacy of 5-aminolevulinic
acid–induced protoporphyrin IX in vitro. Comparison between human glio-
blastoma cells and other cancer cell lines. Photochem Photobiol Sci 6, 145–151.
[22] Humphries MJ (2001). Cell adhesion assays. Mol Biotechnol 18, 57–61.
[23] Underwood PA and Bean PA (1998). Extracellular matrix interferes with color-
imetric estimation of cell number. In Vitro Cell Dev Biol Anim 34, 200–202.
[24] Kunzi-Rapp K, Genze F, Küfer R, Reich E, Hautmann RE, and Gschwend JE
(2001). Chorioallantoic membrane assay: vascularized 3-dimensional cell culture
system for human prostate cancer cells as an animal substitute model. J Urol
166, 1502–1507.
[25] Giannoni E, Fiaschi T, Ramponi G, and Chiarugi P (2009). Redox regulation
of anoikis resistance of metastatic prostate cancer cells: key role for Src and
EGFR-mediated pro-survival signals. Oncogene 28, 2074–2086.
[26] Bertram J, Peacock JW, Tan C, Mui AL, Chung SW, Gleave ME, Dedhar S,
Cox ME, and Ong CJ (2006). Inhibition of the phosphatidylinositol 3′-kinase
pathway promotes autocrine Fas-induced death of phosphatase and tensin
homologue-deficient prostate cancer cells. Cancer Res 66, 4781–4788.
[27] Edick MJ, Tesfay L, Lamb LE, Knudsen BS, and Miranti CK (2007). Inhibi-
tion of integrin-mediated crosstalk with epidermal growth factor receptor/Erk
or Src signaling pathways in autophagic prostate epithelial cells induces caspase-
independent death. Mol Biol Cell 18, 2481–2490.
[28] Roca H, Varsos ZS, and Pienta KJ (2009). CCL2 is a negative regulator of AMP-
activated protein kinase to sustainmTOR complex-1 activation, survivin expression,
and cell survival in human prostate cancer PC3 cells. Neoplasia 11, 1309–1317.
[29] Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, chal-
lenges and limitations. Nat Rev Cancer 9, 550–562.
[30] Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM (2005). Phosphorylation
and regulation of Akt/PKBby the rictor-mTOR complex. Science 307, 1098–1101.
[31] McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell
ED, Bally MB, Foster LJ, and Dedhar S (2008). Rictor and integrin-linked ki-
nase interact and regulate Akt phosphorylation and cancer cell survival. Cancer
Res 68, 1618–1624.
[32] Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, and
Dedhar S (2000). Inhibition of integrin-linked kinase (ILK) suppresses activa-
tion of protein kinase B/Akt and induces cell cycle arrest and apoptosis of
PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97, 3207–3212.
[33] McDonald PC, Fielding AB, and Dedhar S (2008). Integrin-linked kinase—
essential roles in physiology and cancer biology. J Cell Sci 121, 3121–3132.
[34] Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M, and Jones JC (2008).
Laminin-332–integrin interaction: a target for cancer therapy? Curr Med Chem
15, 1968–1975.
[35] Marinkovich MP (2007). Tumour microenvironment: laminin 332 in squamous-
cell carcinoma. Nat Rev Cancer 7, 370–380.
[36] Guess CM and Quaranta V (2009). Defining the role of laminin-332 in carci-
noma. Matrix Biol 28, 445–455.
[37] Calaluce R, Bearss DJ, Barrera J, Zhao Y, Han H, Beck SK, McDaniel K, and
Nagle RB (2004). Laminin-5 β3A expression in LNCaP human prostate carci-
noma cells increases cell migration and tumorigenicity. Neoplasia 6, 468–479.
[38] Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL, and
Ellis V (2010). Pericellular activation of hepatocyte growth factor by the trans-
membrane serine proteases matriptase and hepsin, but not by the membrane-
associated protease uPA. Biochem J 426, 219–228.
[39] Tripathi M, Potdar AA, Yamashita H, Weidow B, Cummings PT, Kirchhofer
D, and Quaranta V (2011). Laminin-332 cleavage by matriptase alters motility
parameters of prostate cancer cells. Prostate 71, 184–196.
Neoplasia Vol. 13, No. 7, 2011 Hepsin Modulates Adhesion and AKT Signaling Wittig-Blaich et al. 589
Reference
[1] Angelloz-Nicoud P, Lalou C, and Binoux M (1998). Prostate carcinoma (PC-3)
cell proliferation is stimulated by the 22-25-kDa proteolytic fragment (1-160)
and inhibited by the 16-kDa fragment (1-95) of recombinant human insulin-
like growth factor binding protein-3. Growth Horm IGF Res 8(1), 71–75.
Figure W1. Western blot analysis of 5 μg of ECM deposited by
RWPE1 and PC3L1-VC cells during 6 days of growth to confluence
revealed the presence of a ∼140-kDa band corresponding to
LAMB3 in RWPE1- (RW) but not PC3L1-VC– (PC) derived ECM.
Figure W2. Semiquantitative analysis of changes in AKT phosphory-
lation at Ser473 in PC3L1-HPN after full hepsin induction on different
ECM substrates over time. An image file of the Western blot de-
picted in Figure 5D was subjected to band intensity analysis using
GeneTools Software (Syngene, Cambridge, United Kingdom). For
each blot, a ROI was fitted to band size, multiplied and used for den-
sitometry of individual bands. Values were background-corrected
using an automatic algorithm implemented in the software package.
(A) For the individual cell populations, we initially calculated signal in-
tensity ratios of pAKTSer473 versus AKT, which reflect relative AKT
phosphorylation states at Ser473 in the respective samples. (B) To de-
termine alterations in phosphorylation states after hepsin induction
on the different ECM substrates, we calculated ratios of Ser473 phos-
phorylation in the induced versus uninduced state.
Figure W3. As previously demonstrated by others, the broad-
spectrum serine protease inhibitor AEBSF suppresses proteolytic
activity in cell culture at a concentration of 100 μM [1]. We used
AEBSF at 100 μM to examine whether inhibition of gross serine
protease activity abolishes the effects exerted by the graded over-
expression of hepsin in PC3 cells. A total of 5000 cells/well were
seeded in 96-well plates and treated with AEBSF and various con-
centrations of dox as indicated. AEBSF did not restore viability
after graded overexpression of hepsin but instead already caused
a significant loss of viability in PC3L1-HPN (P = 3.0e − 12) and
PC3L1-VC (P = .007) cell populations, which were not induced
by dox. Viability was measured 72 hours after drug treatment; cell
survival was calculated as percentages of the untreated controls,
respectively (mean ± SD of four experiments performed in tripli-
cate, two-tailed t test).
